ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • Immune cell discovery offers new potential for cancer immunotherapy
    on October 28, 2024 at 9:00 am

    Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity. The pre-clinical findings, published in Nature, highlight the potential to activate these cells to fight tumors more effectively, offering new hope for broader treatment success, particularly in patients with cancer that is unresponsive to current immunotherapies.

  • Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
    on October 25, 2024 at 8:00 am

    Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019. It leverages Dewpoint's proprietary platform for biomolecular condensates and Bayer's small molecule R&D capabilities to develop new treatments for cardiovascular and renal diseases.

  • Repurposing mifepristone: new hope for anti-aging treatments
    on October 24, 2024 at 8:00 am

    New research from biologists at the USC Dornsife College of Letters, Arts and Sciences reveals that mifepristone, a drug best known for its use for ending early pregnancies, might also extend lifespan. The findings could pave the way for anti-aging treatments. Mifepristone, which is also used to treat Cushing's disease and certain cancers, has caught the attention of scientists exploring ways to promote longer, healthier lives.

  • U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
    on October 23, 2024 at 8:00 am

    Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older.

  • Expanding access to weight-loss drugs could save thousands of lives a year
    on October 22, 2024 at 8:00 am

    Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United States, according to a new study led by researchers at Yale School of Public Health and the University of Florida. The findings highlight the critical need to remove existing barriers that are hindering people's access to effective weight loss treatments and impeding public health efforts to address the national obesity crisis, the researchers said.